BeiGene

394 articles with BeiGene

• BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity

  3/30/2023

  BeiGene, a global biotechnology company, announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately.

• BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

  3/21/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence.

• BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results

  2/27/2023

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.

• BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference

  2/24/2023

  BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference.

• BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

  2/24/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the China National Medical Products Administration (NMPA) granted approval for the company’s PD-1 inhibitor, tislelizumab.

• BeiGene to Present at Upcoming Investor Conferences - February 1, 2023

  2/1/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences.

• BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia

  1/19/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

• BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

  1/19/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukemia (CLL) and the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

• BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List

  1/18/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS® (carfilzomib), a proteosome inhibitor licensed-in from Amgen.

• BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

  1/17/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium.

• BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

  1/4/2023

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT.

• BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

  12/30/2022

  BeiGene, a global biotechnology company announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental biologics license application for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma.

• 

  BeiGene’s Brukinsa Outshines Janssen’s Imbruvica in Comparison Trial  

  12/14/2022

  In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). 

•  BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

  12/13/2022

  BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

• BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors

  12/9/2022

  BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

• BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022

  11/22/2022

  BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA ®  Versus IMBRUVICA ®  in Late-Breaking Oral Session at ASH 2022.

• BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

  11/17/2022

  BeiGene Receives European Commission Approval for BRUKINSA ® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL).

• BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care

  11/15/2022

  BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care.

• BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers

  11/10/2022

  BeiGene Announces Brazil Approvals for BRUKINSA ® As a Treatment for Rare Blood Cancers.

• BeiGene Reports Third Quarter 2022 Financial Results

  11/9/2022

  BeiGene, Ltd. today reported financial results for the third quarter of 2022, recent business highlights, and anticipated upcoming milestones.